Skin epithelioid hemangioma

Summary

Skin epithelioid hemangioma (MONDO:0001939) is a disease. A subtype of skin hemangioma — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	skin epithelioid hemangioma
Mondo ID	MONDO:0001939
DOID	DOID:14308
NCIT	C7393
SNOMED CT	400131007
UMLS	C0002989
MedGen	297
GARD	0027042
Anatomy (UBERON)	UBERON:0000014
Is cancer (heuristic)	no

Also known as: angiolymphoid cutaneous hyperplasia · angiolymphoid hyperplasia of skin · angiolymphoid hyperplasia of the skin · epithelioid hemangioma of skin · epithelioid hemangioma of the skin · histiocytoid hemangioma of skin · histiocytoid hemangioma of the skin · histiocytoid hemangioma of zone of skin · skin epithelioid hemangioma · zone of skin histiocytoid hemangioma

Disease family

This is a subtype of skin hemangioma. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: human disease › disease by etiologic mechanism › cancer or benign tumor › neoplastic disease or syndrome › neoplasm › benign neoplasm › cardiovascular organ benign neoplasm › benign blood vessel neoplasm › hemangioma › skin hemangioma › skin epithelioid hemangioma

Related subtypes (9): cherry hemangioma, angiokeratoma, scrotal hemangioma, tufted angioma, verrucous hemangioma, Wyburn-Mason syndrome, Cobb syndrome, angioma serpiginosum, eyelid capillary hemangioma

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 0.